Sanofi partners up for 'organ on a chip'; Relmada hauls in $8M;

@FierceBiotech: Most popular story on our website in Sept.: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Story | Follow @FierceBiotech

@JohnCFierce: Pretty clear that Perlmutter now becomes the head wheeler dealer at Merck. Good role for him. Buying and selling. | Follow @JohnCFierce

@DamianFierce: Amid all this talk of axing jobs, have a look at FierceBiotech's rundown of just how much R&D chiefs get paid. Top 15 highest paid biopharma R&D chiefs | Follow @DamianFierce

> Sanofi ($SNY) has united with New Jersey's HμREL to develop "organ on a chip" technology for preclinical research. Article

> Relmada Therapeutics landed an $8 million Series A to fund its pipeline of chronic pain treatments. News

> Texas' Lexicon Pharmaceuticals ($LXRX) posted positive proof-of-concept results for LX4211, a drug designed to treat renal impairment in patients with Type 2 diabetes. More

Medical Device News

@FierceMedDev:  | Follow @FierceMedDev

@MarkHFierce: Two U.S. insurers will now cover MDxHealth's prostate cancer Dx test--a major win. It's hard to get coverage. Press release | Follow @MarkHFierce

@MichaelGFierce: MIT nanoparticles help deliver vaccines to mucosal surfaces. More from FierceDrugDelivery | Follow @MichaelGFierce

> PerkinElmer expands MA life sciences research presence. Article

> Report: Blackstone, Bain, other equity firms bid for J&J's Dx unit. More

Pharma News

@FiercePharma: It's official: Roche's Perjeta nabs speedy  nod in early breast cancer. Kadcyla next? Story | Follow @FiercePharma

@CarlyHFierce: Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds. ICYMI yesterday | Follow @CarlyHFierce

> Lilly fails to persuade Medicare to pay for Alzheimer's imaging drug. More

> FDA approves Lundbeck, Takeda antidepressant Brintellix. Article

> Merck to slash 8,500 jobs in $2.5B global overhaul. Story

Biotech Research News

@EmilyMFierce: What happens to the FDA in a government shutdown? ICYMI from FierceBiotech | Follow @EmilyMFierce

> New approach could treat common childhood brain cancer. Report

> Antidepressants could provide new way to treat deadly lung cancer. More

> Antifungal drug abolishes HIV in cells. Article

> New approach could treat common childhood brain cancer. Story

> Evolva in talks with U.S. government for $14.7M antibacterial contract. Item

Pharma Manufacturing News

@EricPFierce: Growing Bayer HealthCare gets new leader. Pfizer exec Olivier Brandicourt takes over top job Nov. 1. ICYMI from FiercePharma | Follow @EricPFierce

> Legislation defines when FDA can take action against compounders. Story

> GSK opens $40M plant in Cork, Ireland, adding 20 jobs. More

> Merck joins Bahrain venture. News

> FDA plant inspections continue, even in government chaos. Item

> Boehringer Ingelheim Shanghai plant tripling capacity. Article

And Finally... What happens to science and technology during a government shutdown? Feature

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.